TABLE 3.
Outcomes and Complications Stratified by Treatment Cohort
| Combined Cohort (n = 11) | Surgical Cohort (n = 10) | P | |
|---|---|---|---|
| Outcomes | |||
| Local recurrence (%) | 4 (19) | 10 (38.5) | <0.01 |
| Location of recurrence | |||
| Axilla | 1 | 3 | |
| Inguinal fold | 0 | 2 | |
| Groin/genital/perinea | 3 | 3 | |
| Breast | 0 | 2 | |
| Time to recurrence, from closure, mo | |||
| Mean (range) | 18.5 (4–30) | 6 (1.5–15) | <0.001 |
| Time to recurrence, from cessation of biologics, mo | |||
| Mean (range) | 10.5 (2.5–15)* | N/A | |
| Disease progression/development of new lesions | 2 (18) | 5 (50) | <0.001 |
| Time to progression, from closure, mo | |||
| Mean (range) | 18 (16–20) | 8.5 (4–10.5) | <0.05 |
| Time to progression, from cessation of biologics, mo | |||
| Mean (range) | 10.5 (9–12) | N/A | |
| Complications | |||
| Incisional wound dehiscence | 0 | 1 | |
| Surgical-site infection | 0 | 2 | |
| Delayed wound healing | 2 | 0 | |
| Adverse events related to biologic therapy | 0 | N/A | |
*
Recurrence occurred in 1 patient after 4 months of active treatment with infliximab. N/A, Not Applicable.